Citigroup Maintains Neutral on Neurocrine Biosciences, Lowers Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang maintains a Neutral rating on Neurocrine Biosciences (NBIX) and lowers the price target from $141 to $140.

February 08, 2024 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup analyst David Hoang maintains a Neutral rating on Neurocrine Biosciences and lowers the price target from $141 to $140.
The adjustment in price target by Citigroup is minor, suggesting a stable outlook on NBIX with no significant short-term price movement expected. The Neutral rating indicates that the analyst sees the stock as fairly valued at its current price, implying limited upside or downside potential in the short term.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 90